CBD Oil for Sleep and Relapsing Polychondritis: Tracheal Collapse Fear, Audiovestibular Tinnitus and Vertigo, and Cartilage Vigilance Hyperarousal

CBD Oil and Relapsing Polychondritis Medications: Dapsone CYP2C9, Colchicine P-gp/CYP3A4, and the Biologic Profile

Dapsone (diaminodiphenylsulfone) for mild RP — CYP2C9 substrate, methemoglobinemia risk at elevated levels: Dapsone is an antimicrobial and anti-inflammatory sulfonamide used in mild-to-moderate RP (particularly for auricular and nasal chondritis and articular disease) as a corticosteroid-sparing agent. Dapsone is primarily metabolized by CYP2C9 (N-hydroxylation to the hydroxylamine metabolite that causes methemoglobinemia) and CYP3A4. CBD is a moderate-to-strong CYP2C9 inhibitor at supplemental doses — CYP2C9 inhibition reduces dapsone clearance, increasing plasma dapsone levels. Elevated dapsone levels increase the risk of methemoglobinemia (conversion of hemoglobin to methemoglobin by the dapsone hydroxylamine metabolite, reducing oxygen-carrying capacity) and hemolytic anemia. Clinical significance: dapsone has a relatively narrow therapeutic window for methemoglobinemia risk; significant CYP2C9 inhibition could push plasma levels into the range where methemoglobin production becomes clinically relevant. Physician disclosure and dapsone level/methemoglobin monitoring is mandatory before combining CBD with dapsone. This is the most RP-specific drug interaction in this post and differs from all prior posts: dapsone is used in few other conditions in this series, making CYP2C9-dapsone the distinctive interaction here.

Colchicine for acute RP flares — CYP3A4 and P-gp substrate, narrow therapeutic window: Colchicine (a microtubule-disrupting anti-inflammatory) is used in some RP patients for acute flare management and articular disease. Colchicine is a CYP3A4 and P-glycoprotein (P-gp) substrate with an extremely narrow therapeutic window — the difference between therapeutic and toxic plasma levels is small, and GI toxicity (nausea, vomiting, diarrhea) and, at higher levels, myopathy and bone marrow suppression occur at modestly elevated plasma concentrations. CBD inhibits both CYP3A4 and P-gp, potentially increasing colchicine plasma levels. Physician disclosure before combining CBD with colchicine is important — the narrow therapeutic window makes any pharmacokinetic interaction more clinically consequential than it would be for drugs with wider margins. The risk is highest during acute flare management when colchicine doses may already be at the upper end of the therapeutic range.

Prednisone/prednisolone for moderate-to-severe RP — modest CYP3A4 interaction: Corticosteroids remain the most common treatment for moderate-to-severe RP flares and for laryngotracheal disease. Prednisone undergoes CYP3A4 metabolism to prednisolone (its active form); prednisolone is further metabolized by CYP3A4. CBD's CYP3A4 inhibition may modestly increase prednisolone exposure — clinical significance at supplemental CBD doses is low but awareness is appropriate. Physician disclosure is appropriate, particularly for patients on long-term low-dose prednisolone for maintenance.

Methotrexate for chronic RP — no CYP interaction, hepatotoxicity monitoring shared across immunosuppressed posts: Methotrexate is used in chronic RP for disease modification and corticosteroid sparing, particularly for articular and mucocutaneous disease. Methotrexate is renally cleared with no significant CYP metabolism — no pharmacokinetic interaction with CBD. The hepatotoxicity monitoring (liver function tests) shared across all methotrexate-using posts in this series applies here; CBD's hepatic effects at high doses are a known concern and LFT monitoring with both agents is prudent.

Tocilizumab (IL-6 inhibitor) and rituximab (anti-CD20) for refractory RP — no CYP metabolism, same profile as prior posts: Both tocilizumab and rituximab are used in refractory RP. Tocilizumab is metabolized by proteolytic degradation with no CYP involvement. Rituximab similarly undergoes proteolytic clearance. Note: the tocilizumab CYP3A4 normalization reversal described in P11-252 (AOSD) applies here if RP occurs in the context of active IL-6-driven inflammation, though RP's primary driver is type II collagen autoimmunity rather than IL-6 excess — the reversal interaction is less central here than in AOSD. Azathioprine (used in some RP cases) is metabolized by TPMT (thiopurine methyltransferase) rather than CYP — no significant CBD interaction.

Laryngotracheal RP: The Tracheal-Collapse-Fear Protocol With Upright-Inclined Sleep Positioning

For people with RP and laryngotracheal involvement — the subgroup with the most severe sleep disruption and the most justified nocturnal anxiety in this post — the protocol is built around 5-HT1A for tracheal asphyxiation fear and TRPV1 for laryngotracheal pain. The Nano CBD Broad Spectrum Oil sublingually sixty to ninety minutes before sleep establishes 5-HT1A occupancy for the peak tracheal-collapse fear window during sleep transition — when the patient moves from alert airway-monitoring to the first unconscious sleep stage and the fear of losing conscious control over tracheal patency is most acute. The cream applied to the anterior neck (over the tracheal and subglottic region externally) provides localized TRPV1 desensitization at the surface sensory afferents of the laryngotracheal region — while the cream does not penetrate to the tracheal mucosa itself, perilaryngeal and cervical skin TRPV1 desensitization reduces the surface dysesthesia and referred pain from active laryngotracheal chondritis. The CBD+CBN+D9+Melatonin Gummies restore N3 architecture disrupted by tracheal-fear awakenings and stridor-related sleep fragmentation, with melatonin addressing the HPA-driven sleep onset delay. Sleep position: for tracheomalacia patients, the lateral decubitus position (side-sleeping) reduces the gravitational collapse of the anterior tracheal wall that occurs in the supine position — a wedge pillow to maintain lateral positioning is an important non-pharmacological adjunct. The Nano CBD Muscle and Joint Cream applied to the anterior neck also addresses any articular or costochondral chondritis present concurrently.

Audiovestibular RP: The Tinnitus Masking and Vertigo-Anchored Protocol

For people with RP and audiovestibular involvement — tinnitus, progressive hearing loss, and/or episodic vestibular vertigo — the protocol addresses the unique nocturnal amplification dynamics of both tinnitus and vertigo. The Nano CBD Broad Spectrum Oil leads with the adenosine reuptake mechanism (ENT1 blockade → adenosine A1/A2A receptor activation → cochlear neural excitability reduction) alongside 5-HT1A for tinnitus distress and hearing loss anxiety attenuation. The critical environmental adjunct for audiovestibular RP: a white noise machine or low-level ambient sound source in the bedroom that restores the masking ambient sound that tinnitus sufferers lose at night — this is not a CBD mechanism but it operates synergistically by reducing the tinnitus-to-ambient ratio at the moment CBD's central gain modulation is active, producing better tinnitus relief than either intervention alone. For vestibular vertigo: gentle head elevation (ten to fifteen degrees above flat, using an adjustable wedge) can reduce the severity of vestibular vertigo in the supine position by shifting the otolith load. The Nano CBD Full Spectrum Berry Gummies are the preferred daytime format for audiovestibular RP patients with high anxiety burden from progressive hearing loss — the full-spectrum entourage effect provides the broadest coverage across the anxiety, pain, and inflammatory channels. The Nano CBD Water-Soluble Broad Spectrum Softgels extend overnight coverage for continuous cochlear anti-inflammatory (CB2) and adenosine-mediated neural support through the second half of the night.

The RP Protocol: Dapsone Disclosure First, Cream for External Chondritis Sites, and PSQI + Tinnitus Log + Tracheal Stenosis Score Tracking

Dapsone disclosure is the non-negotiable first step for any RP patient on dapsone: Before starting CBD oil, any RP patient taking dapsone must disclose the intention to their prescribing physician. The CYP2C9 inhibition by CBD increases dapsone plasma levels with a methemoglobinemia risk that requires monitoring. The conversation with the physician should establish a plan for methemoglobin monitoring (a simple co-oximetry blood test) and dapsone level assessment if symptoms of methemoglobinemia (cyanosis, fatigue, headache, shortness of breath at levels higher than normal) develop. For RP patients on colchicine for acute flares, the same disclosure applies with awareness of the narrow therapeutic window.

Cream for accessible external chondritis sites — ears, nose, costochondral junctions, and accessible joints: The cream has a distinctive application profile in RP because so many of the affected cartilage sites are in external, accessible locations where topical TRPV1 desensitization can be applied directly. Auricular chondritis — the most common RP feature — produces a red, swollen, painful pinna (external ear) that is acutely sensitive to pillow pressure during sleep; the cream applied to the inflamed pinna (avoiding the ear canal) before sleep provides localized TRPV1 desensitization at the auricular sensory afferents, reducing the pillow-pressure allodynia. Nasal chondritis produces pain at the nasal bridge that is accessible to topical application. Costochondral chondritis (pain at the rib-sternum junction) produces chest wall tenderness that can be addressed topically. The cream in RP is more broadly applicable than in most other posts precisely because the disease is an external cartilage disease visible and accessible at the body surface.

PSQI + tinnitus severity index + tracheal stenosis monitoring three-variable tracking: The three-variable tracking system for RP includes the Pittsburgh Sleep Quality Index (PSQI) as the primary sleep outcome; a tinnitus severity measure (the Tinnitus Handicap Inventory or a simple 0–10 nightly tinnitus severity rating) for audiovestibular monitoring; and the patient's awareness of any change in tracheal stenosis symptoms (increasing dyspnea on exertion, new or worsening inspiratory stridor, change in voice quality) as a safety signal — not for CBD to address directly, but to flag for urgent pulmonology evaluation when present.

Does CBD oil help with the fear of tracheal collapse during sleep — and is this fear medically justified?

The tracheal collapse fear in RP is one of the most medically justified nocturnal fears in this entire series — unlike anxiety disorders where the feared outcome is improbable, laryngotracheal RP with established tracheomalacia carries a real, documented risk of acute respiratory failure from tracheal collapse, and is the leading cause of RP-related mortality. The fear is not irrational; it is a survival response to a genuinely dangerous anatomical situation. Understanding how CBD oil addresses this fear without eliminating appropriate vigilance is important: CBD's 5-HT1A mechanism does not suppress the patient's capacity to respond to genuine respiratory distress — it attenuates the amygdala's chronic broadcast of tracheal-threat signals into round-the-clock physiological hyperarousal during periods when tracheal collapse is not actively occurring. The distinction matters: a patient with tracheomalacia who cannot sleep because they are lying awake hyperventilating in fear of tracheal collapse on every breath is experiencing amygdala-driven hyperarousal that is not adaptive — it doesn't protect the airway, it merely prevents sleep while exhausting the patient. CBD's 5-HT1A attenuation of this hyperarousal allows the patient to sleep without eliminating their capacity to wake if genuine respiratory distress occurs. Tracheal collapse producing obstruction would still wake the patient — the stridor, choking sensation, and acute dyspnea of a real tracheal collapse are powerful arousal stimuli that CBD's anxiolytic mechanism does not suppress. What CBD changes is the pre-sleep and inter-sleep-stage anxiety about the possibility of tracheal collapse: the hyperarousal from imagining it, not the response to actually experiencing it. That said: patients with significant tracheomalacia or subglottic stenosis on imaging or spirometry should have their pulmonologist's awareness and input before relying on CBD for sleep support, because the pulmonologist is better positioned to assess the actual structural severity and the urgency of intervention (tracheal stenting, tracheostomy) relative to symptomatic sleep support.

Can CBD oil reduce tinnitus from relapsing polychondritis, and how is RP tinnitus different from other causes?

CBD oil can reduce the subjective severity of RP-related tinnitus through the adenosine reuptake inhibition mechanism — and understanding how RP tinnitus differs from the more common forms helps explain why this mechanism is relevant. Tinnitus has two primary components: the peripheral generator (the damaged cochlear hair cells or cochlear nerve fibers that produce aberrant electrical signals) and the central amplifier (the central auditory cortex increases its gain in response to reduced peripheral input, amplifying the aberrant signal into the subjective tinnitus percept — this "central gain" phenomenon is why tinnitus from noise exposure or ototoxicity is often perceived as louder than the peripheral damage alone would generate). RP tinnitus is generated by cochlear vasculitis (ischemic hair cell damage from cochlear artery inflammation) — an active inflammatory process that, unlike age-related or noise-induced tinnitus, may be partially reversible with anti-inflammatory treatment during active cochlear vasculitis, and partially irreversible after hair cell death. CBD's adenosine mechanism — ENT1 blockade increasing extracellular adenosine → A1 receptor activation on cochlear spiral ganglion neurons — reduces the neural hyperexcitability that drives central gain amplification, modestly reducing the central component of tinnitus perception. The peripheral generator (damaged hair cells) is not directly reversed by CBD. The practical effect: CBD may reduce tinnitus severity by fifteen to thirty percent in patients with significant central gain amplification, which is meaningful for the nocturnal amplification that occurs when masking ambient sound disappears. The adenosine mechanism is most relevant during the first three months of audiovestibular RP when cochlear inflammation is active and neural hyperexcitability is at its peak — in established sensorineural hearing loss with purely peripheral hair cell death and no active cochlear inflammation, the CBD tinnitus benefit is more modest. The CB2 anti-inflammatory mechanism may also provide some benefit during active cochlear vasculitis by reducing the inflammatory microenvironment that drives continued hair cell ischemia and neural activation.

How does CBD oil address the saddle nose anxiety in relapsing polychondritis — and does it help with the pre-sleep monitoring rituals?

Saddle nose anxiety in RP is a specific form of body-image-anchored illness anxiety where the object of monitoring is a visible, progressive, and irreversible physical change to the face — the most socially salient and psychologically significant body region for self-identity. The pre-sleep monitoring ritual (nasal bridge palpation, mirror inspection) that many RP patients perform before bed functions as a compulsive reassurance-seeking behavior driven by the uncertainty about whether today's disease activity has advanced the deformity — the same uncertainty-driven checking behavior seen in pre-sleep INR monitoring in APS, but anchored in visible appearance rather than numerical lab value. CBD's 5-HT1A mechanism addresses this monitoring behavior at the anxiety level: the checking behavior is driven by tolerance for uncertainty — the intolerance of not knowing whether the bridge is lower tonight than last night produces the urge to check. 5-HT1A partial agonism increases the prefrontal cortex's capacity to tolerate this uncertainty without requiring the checking behavior to resolve it — the same mechanism that reduces OCD-adjacent compulsive checking in anxiety disorders is relevant here. This doesn't mean CBD eliminates the saddle nose anxiety entirely: the anxiety is not irrational, because the bridge is genuinely changing with each RP flare, and some monitoring has medical value (reporting significant bridge change to the rheumatologist may indicate active nasal chondritis requiring treatment escalation). What CBD's 5-HT1A mechanism changes is the intensity and compulsiveness of the monitoring — from multiple mirror checks and repeated palpation in the hour before sleep to a more proportionate single check that does not dominate the pre-sleep hour. The grief component of saddle nose disfigurement — mourning the pre-disease appearance — is a separate emotional layer that 5-HT1A attenuation can partially modulate but that ultimately benefits from psychological support alongside CBD: cognitive behavioral therapy adapted for illness-related disfigurement anxiety has an evidence base in conditions like vitiligo and alopecia areata and is directly applicable to RP facial disfigurement.

I have relapsing polychondritis and take dapsone — what do I need to know before using CBD oil?

Dapsone and CBD have the most significant pharmacokinetic interaction relevant to RP patients in this post, and the interaction requires physician disclosure and monitoring before proceeding. Here is the complete picture. Dapsone is metabolized by CYP2C9 to its N-hydroxylamine metabolite, which is responsible for methemoglobin production, and by CYP3A4 to other metabolites. CBD is a moderate-to-strong inhibitor of CYP2C9 at supplemental doses. CYP2C9 inhibition by CBD reduces dapsone clearance, increasing steady-state dapsone plasma concentrations. Higher dapsone plasma levels increase the production of the N-hydroxylamine metabolite and therefore increase methemoglobin production. Methemoglobinemia at mild levels (one to three percent methemoglobin, normally less than one percent) produces fatigue, headache, and mild cyanosis; at moderate levels (ten to twenty percent) produces dyspnea, confusion, and chest pain; at severe levels (above twenty percent) produces loss of consciousness and requires urgent treatment with methylene blue. The practical risk assessment: at typical supplemental CBD doses (twenty-five to fifty mg/day), CYP2C9 inhibition is real but the degree of dapsone level increase is unlikely to push a patient on a standard dapsone dose (fifty to one hundred mg/day) into clinically significant methemoglobinemia on its own. The risk is real but moderate, not emergent — it is highest in patients already on higher dapsone doses (one hundred to two hundred mg/day), patients with G6PD deficiency (who are at higher baseline methemoglobinemia risk), or patients on multiple CYP2C9 inhibitors simultaneously. The approach: inform your prescribing physician before starting CBD, provide the initial methemoglobin level as a baseline, and agree on a monitoring plan. If symptoms of methemoglobinemia appear after starting CBD (new fatigue, grey or blue discoloration of fingertips or lips, headache, shortness of breath out of proportion to activity), contact your physician for a co-oximetry test promptly. CBD is not contraindicated with dapsone — it requires co-management.

Does CBD oil help with the auricular chondritis ear pain from sleeping on an inflamed ear?

Auricular chondritis — inflammation of the external ear cartilage (the pinna) — is the most common manifestation of RP, affecting seventy to eighty-five percent of patients, and it produces one of the most specifically nocturnal mechanical pain problems in this entire series: the inflamed pinna is red, swollen, hot, and extremely sensitive to touch, and normal sleeping requires resting the side of the head on a pillow — placing the inflamed pinna under direct mechanical pressure throughout the night. The auricular chondritis sleep disruption from pillow pressure is both pain-driven (the compressive force on the inflamed pinna directly activates the sensitized TRPV1 receptors on the auricular perichondrial and overlying skin sensory afferents) and position-restricted (patients with bilateral auricular chondritis cannot sleep comfortably on either side, and may be forced to sleep supine — which worsens tracheomalacia if laryngotracheal disease is also present). CBD oil addresses auricular chondritis sleep disruption through two routes. Systemic route: the sublingual oil delivers CB2/NF-κB anti-inflammatory coverage to the auricular perichondrium and TRPV1 desensitization to the auricular sensory afferents systemically, reducing both the inflammatory burden of active chondritis and the sensory pain threshold on the pinna. Topical route: the cream applied to the inflamed pinna (the external ear cartilage surface and overlying skin, avoiding the ear canal) before sleep provides direct localized TRPV1 desensitization at the site of pillow-pressure pain — in RP, unlike most other posts where the pain is in deep structures inaccessible to topical application, the auricular pinna is entirely on the body surface and the cream can be applied directly to the inflammatory focus. The mechanical adjunct remains important: a travel pillow with a center cutout (donut-shaped) or a pillow with an auricular channel removes the pinna from mechanical contact with the pillow surface entirely — this is the most effective single intervention for auricular chondritis sleep disruption and should be combined with the CBD cream application for maximum benefit.

How long does CBD oil take to work for relapsing polychondritis sleep disruption, and how do I track whether it's helping?

The timeline for CBD sleep improvement in RP follows distinct patterns for each of the four sleep disruption channels, and understanding which channel is responding first helps interpret the initial weeks of the protocol. For the 5-HT1A tracheal-collapse-fear and multi-site cartilage vigilance anxiety attenuation — the dominant channels in most RP patients — improvement in the pre-sleep anxiety intensity and the body-scan vigilance duration typically becomes perceptible within one to two weeks of consistent nightly use. Patients on the protocol for these channels often describe the first noticeable change as "I still worry, but I'm not lying awake in the same hypervigilant state for as long before I fall asleep." The tinnitus modulation channel (adenosine/ENT1) for audiovestibular RP follows a slower timeline: the central auditory cortex gain reduction from consistent adenosine receptor upregulation takes two to four weeks to produce noticeable tinnitus severity reduction, and the tinnitus severity rating on the evening of day fourteen to twenty-eight is the first meaningful data point. For auricular chondritis pain from pillow contact — addressed by the cream's topical TRPV1 desensitization — improvement begins within the first one to two weeks of consistent nightly application, as TRPV1 receptor downregulation at the pinna surface reduces allodynia to pillow pressure. For the deeper chronic multi-site cartilage pain (articular and costochondral chondritis) — the systemic TRPV1 and CB2 channels — the four-to-eight-week timeline applies. Three-variable tracking for RP: the PSQI as the primary sleep outcome; a simple 0–10 nightly tinnitus severity rating (or the Tinnitus Handicap Inventory at weeks zero, four, eight, and twelve) for the audiovestibular channel; and the patient's own nasal bridge and tracheal symptom log for disease progression monitoring. The twelve-week assessment point captures all four channels at near-maximum effectiveness and provides the clearest picture of the overall CBD sleep support in RP.

Medical Disclaimer

This article is for informational and educational purposes only. It is not intended to diagnose, treat, cure, or prevent any disease or medical condition, including relapsing polychondritis. CBD oil is not a substitute for rheumatological care, pulmonology evaluation for laryngotracheal involvement, or any physician-directed treatment for RP. Patients taking dapsone must disclose CBD use to their physician before beginning, as CBD inhibits CYP2C9 and may increase dapsone plasma levels with methemoglobinemia risk. Patients with laryngotracheal RP or known tracheomalacia must have pulmonologist awareness before adjusting their sleep management approach. CBD oil has not been evaluated as a treatment for relapsing polychondritis or any of its manifestations. The statements in this article have not been evaluated by the Food and Drug Administration. CBD products are not intended to diagnose, treat, cure, or prevent any disease. Individual responses to CBD vary significantly.